Dareplane: a modular open-source software platform for BCI research with application in closed-loop deep brain stimulation.

Objective - This work introduces Dareplane, a modular and broad technology- agnostic open source software platform for brain-computer interface research with an application focus on adaptive deep brain stimulation (aDBS). One difficulty for investigating control approaches for aDBS resides with the complex setups required for aDBS experiments, a challenge Dareplane tries to address. Approach - The key features of the platform are presented and the composition of modules into a full experimental setup is discussed in the context of a Python- based orchestration module.

Master classes of the tenth international brain-computer interface meeting: showcasing the research of BCI trainees.

The Tenth International brain-computer interface (BCI) meeting was held June 6-9, 2023, in the Sonian Forest in Brussels, Belgium. At that meeting, 21 master classes, organized by the BCI Society's Postdoc & Student Committee, supported the Society's goal of fostering learning opportunities and meaningful interactions for trainees in BCI-related fields. Master classes provide an informal environment where senior researchers can give constructive feedback to the trainee on their chosen and specific pursuit.

Perspectives of Implementation of Closed-Loop Deep Brain Stimulation: From Neurological to Psychiatric Disorders.

Background: Deep brain stimulation (DBS) is a highly efficient, evidence-based therapy to alleviate symptoms and improve quality of life in movement disorders such as Parkinson's disease, essential tremor, and dystonia, which is also being applied in several psychiatric disorders, such as obsessive-compulsive disorder and depression, when they are otherwise resistant to therapy.

Summary: At present, DBS is clinically applied in the so-called open-loop approach, with fixed stimulation parameters, irrespective of the patients' clinical state(s). This approach ignores the brain states or feedback from the central nervous system or peripheral recordings, thus potentially limiting its efficacy and inducing side effects by stimulation of the targeted networks below or above the therapeutic level.